CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
This article was sponsored by AstraZeneca.
An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
November 26th 2016
Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.
November 23rd 2016
The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.
September 16th 2016
Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.
September 9th 2016
There are now more personalized treatment options for patients with CLL.
August 31st 2016
Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL.
July 26th 2016
As new therapies get approved and continue to be investigated, treatment for CLL is rapidly evolving.
May 10th 2016
The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits.
April 11th 2016
The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.
April 5th 2016
The treatment landscape of chronic lymphocytic leukemia is rapidly evolving, according to Jeffrey Jones, an assistant professor at The Ohio State University Comprehensive Cancer Center.
April 1st 2016
The landscape for treating CLL is changing, bringing about questions and hope for a cure.
March 18th 2016
Patients taking novel treatments for CLL, and their caregivers, should know which side effects to expect — and recognize when they become emergencies.
March 5th 2016
In the phase 3 RESONATE-2 study, Imbruvica improved progression-free survival (PFS) by 84 percent in previously untreated patients with CLL or SLL.
January 19th 2016
The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.
January 19th 2016
Ed chronicles part II of his chronic lymphocytic leukemia (CLL) story from the third person.
January 8th 2016
In an interview with CURE, John C. Byrd discusses the efficacy of acalabrutinib and how it compares with Imbruvica.
December 11th 2015
Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.
December 8th 2015
The results showed a two-year overall survival rate of 98 percent with Imbruvica.
December 1st 2015
CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.
November 24th 2015
Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
November 19th 2015
A phase 3 study exploring Zydelig in combination with Treanda and Rituxan for patients with previously treated CLL has been stopped early following a positive interim analysis.
November 4th 2015
Ed chronicles his chronic lymphocytic leukemia (CLL) story from the third person.
October 15th 2015
By donating stem cells through Be The Match, healthy adults can save the lives of people with blood cancers.
August 21st 2015
Watching, waiting and then choosing from a bevy of new treatments can be a good strategy for many with CLL.
August 15th 2015
The investigational agent venetoclax has successfully met the primary endpoint of a phase 2 study as a treatment for patients with high-risk relapsed or refractory chronic lymphocytic leukemia.
June 2nd 2015
Adding the targeted drug Imbruvica to a standard combination treatment reduced the risk of disease progression by 80 percent compared with the standard combination alone in patients with pretreated CLL or SLL.
May 6th 2015
A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.
April 29th 2015
The efficacy of Imbruvica (ibrutinib) and Zydelig (idelalisib) in chronic lymphocytic leukemia (CLL) suggests the drugs could potentially replace chemoimmunotherapy completely for some patients.
January 21st 2015
The vastly improved outlook for patients with chronic lymphocytic leukemia (CLL) was named the American Society of Clinical Oncology's inaugural "Cancer Advance of the Year."
December 27th 2014
The FDA has updated the label for Gazyva (obinutuzumab) plus chlorambucil to include data from stage 2 of the phase 3 CLL11 study, which detailed an improvement in progression-free survival as a frontline treatment for patients with chronic lymphocytic leukemia.